Test Price
2,800 AED✅ Home Collection Available
IFRD1 Gene Spinocerebellar Ataxia Type 18 (Autosomal Dominant) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
This DHA‑licensed genetic test delivers 99.9% analytical sensitivity for pathogenic IFRD1 variants using ISO‑certified targeted NGS with confirmatory Sanger sequencing. Patients receive VIP mobile phlebotomy (daily 8 AM–11 PM) for peripheral blood collection, temperature‑controlled cold‑chain logistics, and unlimited telephonic post‑test clinical guidance. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The IFRD1 (SCA18) Genetic Test sequences all coding exons and intron–exon boundaries of the IFRD1 gene to detect autosomal dominant mutations causing spinocerebellar ataxia type 18, a progressive neurodegenerative disorder. This definitive molecular diagnosis guides treatment planning, prognostic counselling, and family risk assessment.
| Feature | Our IFRD1 (SCA18) NGS Test | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, 100% specificity for IFRD1 | Broad but diluted; lower per‑gene coverage |
| Methodology | Targeted NGS with Sanger validation of all variants | Shotgun NGS; incidental findings common |
| Turnaround Time | 3–4 weeks (dedicated single‑gene workflow) | 6–8 weeks (complex bioinformatics pipeline) |
Physician Insight & Safety Protocols
“A positive IFRD1 result must always be interpreted alongside a full neurological examination and three‑generation family pedigree. Genetic testing is a powerful tool, but it is never a standalone diagnosis. I strongly encourage pre‑ and post‑test counselling to ensure every family understands the implications for future health and reproductive decisions. As your DHA‑licensed clinical advisor, I am committed to walking with you through every step.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Information
Do not discontinue prescribed medication without consulting your doctor. Genetic test results do not replace clinical assessment, and abrupt changes in treatment can lead to severe neurological deterioration.
Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Recent blood transfusion (within 4 weeks), active infection with high fever, inability to provide blood or DNA sample, unconfirmed family linkage documentation.
- Emergency Red Flags (seek immediate medical care): Sudden loss of balance or inability to walk, new‑onset dysphagia (choking), double vision with severe headache, loss of consciousness.
Patient FAQ & Clinical Guidance
1. What is the IFRD1 genetic test for spinocerebellar ataxia type 18?
This targeted test analyzes the IFRD1 gene to confirm an autosomal dominant mutation causing SCA18. It uses next‑generation sequencing with Sanger confirmation to achieve 99.9% diagnostic accuracy.
2. How accurate is this genetic test?
The test delivers 99.9% analytical sensitivity and specificity by focusing exclusively on all IFRD1 coding regions and splice sites, minimizing off‑target noise.
3. Will my insurance cover the 2800 AED cost?
We verify direct billing eligibility within minutes via WhatsApp. Send your insurance card photo to +971 54 548 8731 for immediate confirmation.
4. What specialists should I consult before and after testing?
A neurologist, a certified genetic counsellor, and a molecular geneticist guide your decision‑making for accurate interpretation and family risk assessment.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with the Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed in accordance with UAE health data regulations. Your privacy and clinical safety remain our highest priority.
Clinical & Logistical Metadata
| Test Name | IFRD1 Gene Spinocerebellar Ataxia Type 18 (Autosomal Dominant) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3 mL EDTA) |
| Methodology Used | Targeted Next‑Generation Sequencing (NGS) with Sanger confirmation |
| ICD-10-CM Code | G11.8 |
| LOINC Code | 81325-1 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians